Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 7Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma 1Peritoneal Neoplasms 1Ovarian Diseases 1Microsatellite Instability 1Gestational Trophoblastic Neoplasias (GTN) 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Gemcitabine 7Cyclophosphamide 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × avelumab × Gynecologic × Clear all
NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡